Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases

SIMPLE SUMMARY: The interaction of programmed cell death ligand-1 (PDL1) with its receptor PD1 inhibits T-cell responses. Blockade of this interaction with monoclonal antibodies leads to major antitumor effects. However, not all cancer patients respond well to anti-(PD-1/PD-L1) immunotherapy. The PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailly, Christian, Thuru, Xavier, Quesnel, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233757/
https://www.ncbi.nlm.nih.gov/pubmed/34204509
http://dx.doi.org/10.3390/cancers13123034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233757/
https://www.ncbi.nlm.nih.gov/pubmed/34204509
http://dx.doi.org/10.3390/cancers13123034

Ejemplares similares